Endoscopy 2015; 47(07): 617-625
DOI: 10.1055/s-0034-1391712
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Cystic pancreatic neuroendocrine tumors: outcomes of preoperative endosonography-guided fine needle aspiration, and recurrence during long-term follow-up[*]

Wiriyaporn Ridtitid**
1   Indiana University School of Medicine, Indianapolis, Indiana, USA
2   Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
,
Houssam Halawi**
1   Indiana University School of Medicine, Indianapolis, Indiana, USA
,
John M. DeWitt
1   Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Stuart Sherman
1   Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Julia LeBlanc
1   Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Lee McHenry
1   Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Gregory A. Coté
1   Indiana University School of Medicine, Indianapolis, Indiana, USA
,
Mohammad A. Al-Haddad
3   Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
› Institutsangaben
Weitere Informationen

Publikationsverlauf

submitted 27. September 2014

accepted after revision 28. Dezember 2014

Publikationsdatum:
12. März 2015 (online)

Preview

Background and study aims: The role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in the diagnosis and management of cystic pancreatic neuroendocrine tumors (PNETs) is unclear. We aimed to compare clinical/endosonographic characteristics of cystic with solid PNETs, determine diagnostic accuracy of preoperative EUS-FNA, and evaluate recurrence rates after resection.

Patients and methods: All patients with cystic or solid PNET confirmed by EUS-FNA between 2000 and 2014 were identified. A matched case-control study compared 50 consecutive patients with cystic PNETs with 50 consecutive patients with solid PNETs, matched by gender and age at diagnosis of index cystic PNET. We compared clinical/endosonographic characteristics, assessed diagnostic accuracy of preoperative EUS-FNA for identifying malignancy, and analyzed tumor-free survival of patients with cystic and solid PNETs.

Results: Cystic PNETs tended to be larger than solid PNETs (mean 26.8 vs. 20.1 mm, P = 0.05), more frequently nonfunctional (96 % vs. 80 %, P = 0.03), and less frequently associated with multiple endocrine neoplasia type 1 (10 % vs. 28 %, P = 0.04). With surgical pathology as reference standard, EUS-FNA accuracies for malignancy of cystic and solid PNETs were 89.3 % and 90 %, respectively; cystic PNETs were less associated with metastatic adenopathy (22 % vs. 42 %, P = 0.03) and liver metastasis (0 % vs. 26 %, P < 0.001). Cystic fluid analysis (n = 13), showed benign cystic PNETs had low carcinoembryonic antigen (CEA), Ki-67 ≤ 2 %, and no loss of heterozygosity. Patients with cystic and solid PNETs had similar recurrence risk up to 5 years after complete resection.

Conclusions: Cystic PNETs have distinct clinical and EUS characteristics, but were associated with less aggressive biological behavior compared with solid PNETs. EUS-FNA is accurate for determining malignant potential on preoperative evaluation. Despite complete resection, recurrence is observed up to 5 years following surgery.

* An earlier version of the abstract was presented at Digestive Disease Week (DDW), 18 – 21 May 2013, Orlando, Florida, USA.


** W. Ridtitid and H. Halawi contributed equally to this study.